Advancing a US Single-Payer Model for Cell and Gene Therapy

This Viewpoint discusses the status of regulatory approval and reimbursement for cell and gene therapies in Europe and the US.

from JAMA Internal Medicine Online First https://ift.tt/XW1y8FL